Menu

1 / 6

FDA warns of rare eye condition causing blindness from GLP-1 weight loss medications

Business - Latest - Google News·8 days ago
#WEKZop70
#world#news#theguardian#naion#risk
Reading 0:00
15s threshold

The US Food and Drug Administration (FDA) has issued a new warning on GLP-1 medications – which can facilitate weight loss – over a rare eye condition that could lead to sudden and permanent blindness .

On Monday, the FDA announced that it is requiring all GLP-1 medications – including Novo Nordisk’s Ozempic and Wegovy, Eli Lilly’s Mounjaro and Zepbound, as well as Sanofi’s Soliqua – to include information about the potential risk of nonarteritic anterior ischemic optic neuropathy, also known as NAION, on warning labels.

NAION is a rare condition involving sudden reduction of blood flow to the optic nerve, in turn resulting in acute, painless, decreased vision in one eye, including permanent vision loss, the FDA warned.

Common risk factors of NAION include diabetes, smoking, hypertension, as well as hypercholesterolemia. It is the most common cause of acute optic nerve injury in individuals over 50 years old, with an annual average of 2.3 to 10.2 cases out of 100,000 people above that age.…

Continue reading — create a free account

Join HashtagPLUS to read full articles, follow hashtags, vote, and join the conversation.